Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

NCT00189904 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: IMVAMUNE (MVA-BN)

Sponsor

Bavarian Nordic

Collaborators

[object Object]